AstraZeneca Clinical Setbacks Add To Pipeline Woes
Executive Summary
AstraZeneca is terminating development of two Phase III clinical trial programs after they failed to meet their primary endpoints, dealing a blow to the U.K. drug maker's already troubled pipeline
You may also be interested in...
Biotechs Gain On Favorable M&A Landscape; Will Deal Prices Keep Rising?
The steady growth in the valuation of small and mid-size biotech firms over the last quarter may reflect the increasing leverage such companies have in merger and acquisition negotiations with big pharma
Biotechs Gain On Favorable M&A Landscape; Will Deal Prices Keep Rising?
The steady growth in the valuation of small and mid-size biotech firms over the last quarter may reflect the increasing leverage such companies have in merger and acquisition negotiations with big pharma
AstraZeneca Cuts 3,000 Manufacturing Jobs, Pares Down Therapeutic Areas
AstraZeneca's focus on improving manufacturing efficiencies, on the heels of similar moves by Merck and Pfizer, may signal that manufacturing is the next target for industry cost-cutting initiatives